Slide Session 6: Progress in AIDS Vaccine Development

21   Safety and Immunogenicity Study of vCP1452/rgp160 Therapeutic Vaccines in Patients Treated with HAART for Over Two Years.

22   Next Generation Enhanced DNA and Protein Vaccine Approaches Stimulate Potent Immune Responses Against HIV Antigens.

23   Vaccination with VSV G Protein Exchange Vectors Expressing HIV Env and SIV Gag Proteins Protects Rhesus Macaques from Challenge with Highly Pathogenic SHIV 89.6P.

24   Efficient Containment of a Highly Pathogenic Immunodeficiency Virus Challenge by DNA Priming and Recombinant MVA Boosting.

25   Protection from Pathogenic Simian Immunodeficiency Virus (SIV) Infection Correlates with the Rapid Induction of SIV-Specific CD8+ T Cells and Antibodies in Rhesus Macaques Immunized with a Live, Attenuated SIV Vaccine.

26   Rhesus Macaques Vaccinated with Phage-Displayed HIV-1 Epitopes and Subsequently Infected with SHIV- 89.6PD Are Partially Protected Against Disease Progression.

27   Delivery Technologies Enhance Plasmid DNA Vacccination in a Rhesus Macaque Model for HIV.

28   A Polyvalent Envelope Glycoprotein Vaccine Elicits a Broader Neutralizing Antibody Response, but Is Unable To Provide Sterilizing Protection Against a Heterologous SHIV Infection in Pigtailed Macaques.

29   Interactions of Human Dendritic Cells with ALVAC-HIV (vCP205), an HIV-1 Vaccine Candidate.

30   HIV-1 gag-CTL Epitope Mapping in Clade A/E Infected Thai Patients.